Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIL93
- Development stage
- Phase 1
- Lead developer
- Mabworks Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
MIL93 is a recombinant humanized afucosylated IgG1 monoclonal antibody that targets Claudin 18.2 (CLDN18.2), a tumor-associated antigen specifically expressed in the tight junctions of gastric epithelial cells and overexpressed in several malignancies, including gastric, gastroesophageal junction, pancreatic, and biliary tract cancers. By binding to CLDN18.2 on cancer cells, MIL93 induces antitumor activity primarily through enhanced antibody-dependent cellular cytotoxicity (ADCC). Preclinical studies have shown superior activity compared to zolbetuximab. The drug is being developed for the treatment of advanced solid tumors with CLDN18.2 expression and has reached phase 1/2 clinical trials for various gastrointestinal cancers[1][2][3][4][5][6].
- Other names
- anti-claudin 18.2 monoclonal antibody MIL93anti-claudin18.2 monoclonal antibody MIL93anti-claudin-18.2 monoclonal antibody MIL93
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on MIL93.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIL93.